Mutations
no more

About MNM

We combine next-generation AI with the most advanced genomic approaches (whole genome and multiomics data) to save the lives of cancer patients through predictive modeling and drug target identification.

We help patients benefit from scientific discoveries

At MNM, our goal has always been to understand cancer and find the right therapy for every patient. We set out on this journey analyzing somatic variants of patient tumors to guide their therapy. Soon, we realized that there is much more valuable information than only a coding DNA sequence in the patient’s tumor; however, we needed more genomes with clinical data to fully understand cancer origins. We started a BioBank and began building the database of whole-genome sequencing data, which led to the creation of custom data processing pipelines, distributed computation, and storing results in the cloud. With rich datasets at hand, now we can use machine learning to drive our success. We have developed and patented custom CDK4/6i, HRD, and PD1i patient stratification algorithms. The analysis of patient response to existing therapies inspired our broader vision We have realized that our genome analysis technology can reveal patterns of cancer mutations related to genes that are not yet targeted by any therapy. It is this realization that lies at the heart of our unique approach. We do not follow a classical drug target discovery approach - from basic science to in vitro models and clinical trials. Our solution starts from real patient data and leverage AI and bioinformatics to understand mutation profiles and find relevant target candidates. And we are already doing it by creating our drug - MNM177!

To follow this path, we are building a unique field that unites life scientists and data scientists. Together, we can answer questions at the core of cancer development. Together, we can find the right therapy for every cancer patient.

The idea for MutationsNoMore (MNM) was born while we were at Oxford University, where we understood that a new “dictionary” for interpreting a tumor’s mutation language is needed. Over the past four years, we have built technology that translates different mutation types; from single point mutations, structural changes to patterns of mutations into biological insights. Then, we built a new AI framework for these data modalities – our most valuable asset.

We are proud that MNM’s predictive algorithms are used in clinics to help select the right treatment for cancer patients.

Moreover, we are honored that the AI we’ve built has delivered the understanding of tumor vulnerabilities, which are now being used to develop targeted therapy for breast cancer patients.

Pawel Zawadzki & Katarzyna Zawadzka
Co-founder, CEO & Co-founder, COO

MNM in numbers

0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
PhDs
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
AI Experts & Bioinformaticians
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
Molecular Biologists & Geneticists
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
Publications as authors & co-authors
0
1
2
3
4
5
6
7
8
9
 0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
Whole genomes sequenced
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
 0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
Genomic features
weakness
no more

MNM is a biotech start-up created by a interdisciplinary team of experts from geneticists, to molecular biologists, bioinformaticians and AI specialists.

Our team